{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:48:29Z","timestamp":1789213709437,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kamin incentive program, Israel Innovation Authority","award":["53909"],"award-info":[{"award-number":["53909"]}]},{"name":"Kamin incentive program, Israel Innovation Authority","award":["53908"],"award-info":[{"award-number":["53908"]}]},{"name":"Kamin incentive program, Israel Innovation Authority","award":["56619"],"award-info":[{"award-number":["56619"]}]},{"name":"Kamin incentive program, Israel Innovation Authority","award":["56618"],"award-info":[{"award-number":["56618"]}]},{"name":"Kamin incentive program, Israel Innovation Authority","award":["60077902"],"award-info":[{"award-number":["60077902"]}]},{"name":"Kamin incentive program, Israel Innovation Authority","award":["6007795"],"award-info":[{"award-number":["6007795"]}]},{"name":"Eleanor Fox","award":["53909"],"award-info":[{"award-number":["53909"]}]},{"name":"Eleanor Fox","award":["53908"],"award-info":[{"award-number":["53908"]}]},{"name":"Eleanor Fox","award":["56619"],"award-info":[{"award-number":["56619"]}]},{"name":"Eleanor Fox","award":["56618"],"award-info":[{"award-number":["56618"]}]},{"name":"Eleanor Fox","award":["60077902"],"award-info":[{"award-number":["60077902"]}]},{"name":"Eleanor Fox","award":["6007795"],"award-info":[{"award-number":["6007795"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["53909"],"award-info":[{"award-number":["53909"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["53908"],"award-info":[{"award-number":["53908"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["56619"],"award-info":[{"award-number":["56619"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["56618"],"award-info":[{"award-number":["56618"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["60077902"],"award-info":[{"award-number":["60077902"]}]},{"name":"the Aleen and David M. Epstein Fund for Hematology\/Oncology Research","award":["6007795"],"award-info":[{"award-number":["6007795"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Drug resistance remains a major obstacle in cancer treatment despite advances in therapeutic regimens. To address this, we explored the potential of Doxorubicin (Dox) delivery in poly (lactide-co-glycolic acid) (PLGA) nanoparticles to enhance Diffuse large B-cell lymphoma (DLBCL) cell death. This research investigates the potential of Doxorubicin and advanced delivery methods. We used PLGA nanoparticles with Oleyl cysteineamide (OCA); its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs. Compared to PLGA-NPs, PLGA-OCA-NPs enhance immunity and induce tumor cell death. They also show significant apoptotic cell death and induced immune responses in DLBCL mouse models. Dox-conjugated PLGA-OCA-NPs (DOX-OCA) exhibit significant in vitro and in vivo anticancer activity compared to free DOX, showing remarkable antitumor effects with reduced systemic toxicity in mouse models. Our findings underscore the promising potential of PLGA-OCA-NPs in DLBCL treatment, offering a hopeful future in cancer therapy. This innovative delivery system offers enhanced immune responses and effectively addresses toxicity concerns, marking a significant step forward in cancer therapy.<\/jats:p>","DOI":"10.3390\/cells14171334","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:03:14Z","timestamp":1756393394000},"page":"1334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-2024","authenticated-orcid":false,"given":"Ihab","family":"Abd-Elrahman","sequence":"first","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Khairi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Nassar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riki","family":"Perlman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ben Yehuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","article-title":"Evolution of acquired resistance to anti-cancer therapy","volume":"355","author":"Foo","year":"2014","journal-title":"J. Theor. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-13-0131","article-title":"Deja Vu: EGF receptors drive resistance to BRAF inhibitors","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2040620719841581","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: Clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00090","DOI":"10.7554\/eLife.00090","article-title":"Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1","volume":"1","author":"Denard","year":"2012","journal-title":"eLife"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Denard, B., Pavia-Jimenez, A., Chen, W., Williams, N.S., Naina, H., Collins, R., Brugarolas, J., and Ye, J. (2015). Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129233"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tox.2010.03.012","article-title":"Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells","volume":"271","author":"Kahl","year":"2010","journal-title":"Toxicology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.addr.2004.05.002","article-title":"Micro and nano-fabrication of biodegradable polymers for drug delivery","volume":"56","author":"Lu","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155004","DOI":"10.1016\/j.prp.2023.155004","article-title":"Doxorubicin induced epigenetic regulation of dendritic cell maturation in association with T cell activation facilitates tumor protective immune response in non-small cell lung cancer (NSCLC)","volume":"253","author":"Mukherjee","year":"2024","journal-title":"Pathol. Res. Pr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3892\/mmr.2014.2953","article-title":"Picosecond pulsed electric fields induce apoptosis in a cervical cancer xenograft","volume":"11","author":"Jia","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1002\/smll.201301417","article-title":"Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: Efficacy and biofate in a lung cancer mouse model","volume":"9","author":"Karra","year":"2013","journal-title":"Small"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kubacz, M., Kusowska, A., Winiarska, M., and Bobrowicz, M. (2022). In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies. Cancers, 15.","DOI":"10.3390\/cancers15010235"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lu, T.X., Wu, S., Cai, D.Y., Hong, T.T., Zhang, Y., Gao, H.Q., Hua, H.Y., and Wu, X.H. (2019). Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5758-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2016-02-696856","article-title":"Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma","volume":"128","author":"Matthews","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41388-020-01529-z","article-title":"Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma","volume":"40","author":"Nassar","year":"2021","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Aston, W.J., Hope, D.E., Nowak, A.K., Robinson, B.W., Lake, R.A., and Lesterhuis, W.J. (2017). A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3677-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wunderlich, M., Manning, N., Sexton, C., Sabulski, A., Byerly, L., O\u2019Brien, E., Perentesis, J.P., Mizukawa, B., and Mulloy, J.C. (2019). Improved chemotherapy modeling with RAG-based immune deficient mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225532"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.taap.2010.04.011","article-title":"A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery","volume":"246","author":"Nassar","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-08-2502","article-title":"Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases","volume":"15","author":"Carreno","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dorostkar, H., Haghiralsadat, B.F., Hemati, M., Safari, F., Hassanpour, A., Naghib, S.M., Roozbahani, M.H., Mozafari, M.R., and Moradi, A. (2023). Reduction of Doxorubicin-Induced Cardiotoxicity by Co-Administration of Smart Liposomal Doxorubicin and Free Quercetin: In Vitro and In Vivo Studies. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071920"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Schipani, M., Rivolta, G.M., Margiotta-Casaluci, G., Mahmoud, A.M., Al Essa, W., Gaidano, G., and Bruna, R. (2023). New Frontiers in Monoclonal Antibodies for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma. Cancers, 16.","DOI":"10.3390\/cancers16010187"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.2147\/IJN.S432839","article-title":"Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches","volume":"18","author":"Aryal","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:43Z","timestamp":1760034883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":38,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cells14171334"],"URL":"https:\/\/doi.org\/10.3390\/cells14171334","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}